ReviewThe Journal of clinical and aesthetic dermatology2026
Expanding the Topical Therapeutic Landscape for Atopic Dermatitis: A Systematic Review.
Review in The Journal of clinical and aesthetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAtopic dermatitis (AD) is a common chronic inflammatory disease. Despite its global prevalence, the current standard of care has remained unchanged for many years. Historically, first-line agents include topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs). However, these agents have significant limitations, including local and systemic adverse effects. In the last several years, novel topical therapeutic agents have been approved by the United States Food and Drug Administration (FDA) and more are being developed.
objectiveThe present review aims to summarize these topical therapeutic advances and report their efficacy and safety relative to the existing armamentarium.
methodsThree searches were conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and the Agency for Healthcare Research and Quality Methods Guide for Effectiveness and Comparative Effectiveness Reviews guidelines. These included electronic searches of FDALabel (without date restriction) and PubMed and ClinicalTrials.gov (between April 8, 2020 and April 8, 2025).
resultsA total of 52 nongeneric, prescription topical therapeutic agents are currently approved by the FDA for AD, the majority of which are TCS (n=11; 52.4%) and TCIs (n=4; 19.0%). There have been several agents with novel mechanisms of action (n=3; 7.6%) approved by the FDA in recent years, including Janus kinase (JAK) inhibitors, nonsteroidal aryl hydrocarbon receptor (AhR) modulators, and phosphodiesterase 4 (PDE4) inhibitors.
conclusionIn the last 5 years, important innovations in the therapeutic landscape of AD have emerged. Treatments include novel JAK inhibitors, AhR modulators, and PDE4 inhibitors. Adopting these therapies as part of clinical care can improve patients' therapeutic outcomes and quality of life.
Indexed as
Identifiers
42027419PMC13102156What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.